Treatment of acute pain in children aged 1 to less than 18 years.
KETAMINE HYDROCHLORIDE — HIKMA, approved 2023-04-12 (ANDA074524).
4,946 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.